Pear Therapeutics (US)

Press Releases

PEAR Therapeutics to Present at 36th Annual J.P. Morgan Healthcare Conference

BOSTON, and SAN FRANCISCO, January 3, 2018—PEAR Therapeutics, the leader in prescription digital therapeutics, today announced that Corey McCann, M.D., Ph.D., President and CEO of PEAR Therapeutics, will present at the annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2018 at 5:00 pm PST at the Westin St. Francis in San Francisco.

PEAR Therapeutics is a privately-held prescription digital therapeutics company developing clinically validated, FDA-cleared software applications to treat severe medical conditions.

About PEAR Therapeutics

PEAR Therapeutics is the leader in FDA-cleared prescription digital therapeutics. The company’s approach is to integrate clinically-validated software applications with previously approved pharmaceuticals and treatment paradigms to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. PEAR’s lead product, reSET®, is an FDA-cleared 12-week interval prescription therapeutic for Substance Use Disorder (SUD) to be used as an adjunct to standard, outpatient treatment. PEAR’s product development pipeline includes reSET-O™ for opioid use disorder (OUD) and additional prescription digital therapeutics in schizophrenia (THRIVE™), combat post traumatic stress disorder (reCALL™), general anxiety disorder (reVIVE™), pain, major depressive disorder, and insomnia, for which PEAR intends to obtain FDA clearance. For more details, please see


Media contacts:
Karen Sharma or Stefanie Tuck
MacDougall Biomedical Communications